# Major Recall Alert: Miraclox 250mg Powder for Oral Suspension, Miraclox 500mg Capsules, Miraclox 90mg Powder for Oral Drops, Miramox 125mg Powder for Oral Suspension, Miramox 250mg Powder for Oral Suspension, Miramox 500mg Capsules, Mirapicin 125mg Powder for Oral Suspension, Mirapicin 250mg Capsules Recalled Due to Discontinuation of Penicillin-Based Products to Avoid Cross-Contamination and Meet Regulatory Requirements
In a significant development for consumer safety, Miraflash Nigeria Limited has announced the discontinuation of its penicillin-based products, including Miraclox, Miramox, and Mirapicin variations. This move aims to prevent cross-contamination and comply with critical regulatory requirements.
For the millions of consumers relying on these products, here's what you need to know about this recall and the necessary steps to take for your safety.
## Why This Recall is Important
Penicillin-based medications, while effective, pose a heightened risk of cross-contamination during production and packaging. Cross-contamination can introduce penicillin traces into non-related products, potentially leading to severe allergic reactions or compromising product quality.
Miraflash Nigeria Limited has acted proactively, discontinuing the production of the following products:
- **Miraclox 250mg Powder for Oral Suspension**
- **Miraclox 500mg Capsules**
- **Miraclox 90mg Powder for Oral Drops**
- **Miramox 125mg Powder for Oral Suspension**
- **Miramox 250mg Powder for Oral Suspension**
- **Miramox 500mg Capsules**
- **Mirapicin 125mg Powder for Oral Suspension**
- **Mirapicin 250mg Capsules**
The discontinuation aligns with standards set by Nigeria’s National Agency for Food and Drug Administration and Control (NAFDAC).
## Details of the Recall
This recall reflects Miraflash Nigeria Limited’s commitment to consumer safety. The affected penicillin-based products have ceased production, effectively minimizing the risk of cross-contamination. Here’s what you should know:
- **Reason for Recall:** Discontinuation of penicillin-based products to avoid cross-contamination and ensure compliance with regulations.
- **Safety Risks:** Cross-contamination could result in harm, especially in individuals allergic to penicillin. Each instance of unintended exposure comes with potential health risks.
- **Last Production Date:** The recall affects all lots manufactured before the official discontinuation date. Consumers are urged to verify their medications for possible inclusions affected by this directive.
NAFDAC encourages the reporting of any suspected substandard or falsified products to monitor and control risks efficiently.
For more information, visit the official source: [NAFDAC Public Alert No. 032/2025](https://nafdac.gov.ng/public-alert-no-032-2025-alert-on-the-discontinuation-of-the-production-of-penicillin-based-moiety-by-miraflash-2/).
## What You Should Do
Consumers and healthcare providers should take immediate action to ensure safety:
- **Check Product Labels:** Examine your medications to confirm if they’re part of the recall. Look for names such as “Miraclox,” “Miramox,” or “Mirapicin.”
- **Stop Usage if Suspected:** If any product matches the recall, discontinue use and consult a healthcare professional for alternatives.
- **Report Issues to NAFDAC:** If you suspect you’ve purchased a substandard or falsified Miraflash product, file a report directly through the NAFDAC website or their field offices.
Being informed and proactive in this matter will safeguard your health and help regulatory efforts.
## Stay Safe – Get Instant Recall Alerts
Stay informed on safety notices like this. Download [NAFDAC’s official app](https://nafdac.gov.ng/public-alert-no-032-2025-alert-on-the-discontinuation-of-the-production-of-penicillin-based-moiety-by-miraflash-2/) for instant updates on product recalls.
With real-time alerts, you can act quickly to protect yourself, your family, and your community.
Your safety is paramount. Always verify your medications and stay informed about industry updates. Regulatory actions like this one ensure that quality and safety remain top priorities in the pharmaceutical sector. Let’s work together to uphold these standards!